Introduction
Adults living with congenital heart disease (CHD) now outnumber children living with CHD. Within this group, the prevalence of severe CHD has exponentially increased, largely due to improved survival of patients with single-ventricle anatomy who have undergone a Fontan procedure. Although this palliation has allowed such patients to reach adulthood, it has not been without significant consequences. In particular, liver disease is nearly ubiquitous in this population and frequently leaves clinicians scratching their heads with questions about etiology, evaluation, treatment, and prognosis.
Fontan physiology and liver cirrhosis
Complex congenital heart disease characterized by a single functioning ventricle was universally lethal until about 40 years ago when the Fontan procedure was developed [1] . The Fontan has evolved over the past several decades; however, intrinsic limitations exist even in the most ideal conditions [2] . Although this palliation relieves cyanosis and has allowed such patients to reach adulthood, alterations in systemic venous return can lead to elevated systemic venous pressure with chronic passive hepatic congestion and limitation of ventricular filling (due to high preload) thereby reducing cardiac output. Ultimately this can contribute to the development of congestive hepatopathy, liver cirrhosis (LC), and liver failure [3] [4] [5] . It has been suggested that chronic venous congestion in combination with low cardiac output produce hypoxic stress (exacerbated by perioperative insults) and acute or chronic injury that may trigger inflammation and subsequent liver fibrosis (or cirrhosis) [6] .
Laboratory data in these patients usually demonstrate only mild abnormalities even when advanced cirrhosis is present [7] , making assessment of liver dysfunction with tools such as the MELD score [8] of limited clinical value. Consequently, the search for a more meaningful measure of liver function in this population is critical and ongoing at the present time.
Fontan liver pathology
Liver involvement after the Fontan procedure was recognized in the early 1980s when cardiac cirrhosis following the Fontan procedure was first published in a case report [9] . This was followed by the first case series (n= 9) of autopsied patients aged 1-24 years who had undergone a prior Fontan (survival G1-18 years) and showed that the majority had evidence of chronic passive hepatic congestion with half demonstrating centrilobular necrosis or cirrhosis [3] . Centrilobular fibrosis, by definition, affects the area around the central vein and extends along the sinusoids, and so is often referred to as sinusoidal fibrosis ( Fig. 1 ) and has been postulated to result from increased central venous pressure. Subsequent research confirmed the presence of sinusoidal fibrosis in Fontan patients, suggesting that chronic passive congestion is responsible for the liver changes in Fontan patients [4, 10] . A later study predominantly involving pediatric patients reported both sinusoidal and portal-based fibrosis at autopsy, the latter of which is more commonly observed in inflammatory and/or acute hepatitis [11] . Subgroup analysis of patients with the shortest post-Fontan survival in this cohort revealed that Ishak fibrosis stage was associated with longer hospitalization prior to the Fontan and higher pre-Fontan right atrial pressure. This data suggests that there may be liver damage before the Fontan in many single-ventricle patients. The same group demonstrated similar findings (both sinusoidal and portal fibrosis) in an adolescent/young adult cohort (average age 19 years) that underwent liver biopsy after Fontan [12] . Univariate analysis in this cohort indicated that low platelet count correlated with higher fibrosis scores; however, no other variables including traditional measures of synthetic liver function were associated with degree of fibrosis. A subsequent larger postmortem study confirmed the presence of both sinusoidal and portal fibrosis and also showed that longer time to Fontan operation correlated with severity [13] .
In total, this pathologic data suggests that liver disease in this population is the result of both pre-and post-Fontan liver damage, making it difficult to target specific insults. Although pathologic specimens can identify fibrosis/cirrhosis, this does not often correlate with the clinical picture or traditional measures of synthetic function, implying that liver structure and hepatic function are not directly related. This probably explains why common lab tests fail to accurately identify significant liver involvement by traditional measures, such as the MELD score [5] .
Screening-no panacea
The lack of a reliable test(s) to determine severity and progression of liver disease in the Fontan population is a significant clinical problem. Several research groups have evaluated clinical parameters, laboratory values, imaging, and histopathologic specimens to try and determine what studies provide meaningful information Reproduced with permission [13] .
about the state of the liver in Fontan patients. Blood tests that evaluate basic liver function including aminotransferases, alkaline phosphatase, bilirubin, coagulation markers, and protein levels have generally not correlated with degree of liver disease. Blood tests evaluating markers of liver fibrosis such as the AST/platelet ratio index (APRI) [14] , AST/ALT ratio (AAR) [15] [16] [17] , Forns index [18] , cirrhosis discriminant score (CDS) [19] , and Pohl score [20] have not correlated with the degree of liver involvement, nor has the FibroSURE panel (Fibrotest/ActiTest LabCorp, Burlington, NC, USA) which combines α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, γ-glutamyl transferase (GGT), and alanine transaminase along with age and gender to measure fibrosis activity of the liver. Although laboratory data has not reliably correlated with histologic or image-based liver findings, there is some evidence that the model for end-stage liver disease excluding INR (MELD-IX) is associated with increased risk for cardiac mortality or transplantation in the Fontan population [21] .
Pathologic series have identified liver fibrosis and cirrhosis, although initial studies did not correlate these findings with clinical characteristics [22] . When lab tests failed to correlate with degree of liver disease, many clinicians hoped that imaging would correctly identify the extent of liver involvement in Fontan patients, particularly given the knowledge that pathologic disease had been proven. Liver ultrasound, magnetic resonance imaging, and computed tomography have all been evaluated, as have measures of liver stiffness including transient elastography, acoustic radiation force impulse (ARFI), and shear wave elastography (SWE 
Treatment
& There are no guidelines or widely accepted common practice recommendations for prevention or treatment of liver disease in Fontan patients. The most common approach requires consideration of therapies aimed at treating the underlying cardiac problem(s). Here, we review a reasonable approach to screening and prevention, as well as consideration of mechanical support and surgical options.
Screening and prevention
& When adult Fontan patients are transitioned from pediatric to adult care, they frequently have not had evaluation of their liver. Basic blood chemistries and liver function tests including aminotransferases, alkaline phosphatase, γ-glutamyl transferase (GGT), bilirubin, coagulation markers, albumin, and total protein should be assessed when this • Liver nodularity was seen in patients with longer postoperative follow-up
• Post-Fontan hemodynamics correlated with initial GGT, but not late follow-up GGT [37] . Similar recommendations are in place for hepatitis B virus (HBV) screening [38] . The CHD population has been found to have a higher prevalence of HCV than the general population [39, 40] . Adult CHD patients, including those with a prior Fontan, have almost always had prior blood transfusions, and therefore, it is reasonable that they receive a minimum of one-time HCV and HBV screening once transitioned to an adult healthcare provider. If hepatitis B testing is negative and the patient has not received vaccination, it should be offered at this time. & Patients with a prior Fontan palliation are at increased risk for the development of malignant and non-malignant liver lesions [4, 41, 42] . The American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver recommend surveillance in patients at high risk for developing hepatocellular carcinoma (HCC) which include those with cirrhosis from any cause and chronic HBV infection irrespective of cirrhosis [43, 44] . Given the increased risk of HCC as well as non-malignant liver lesions in the Fontan patient, it is reasonable to provide the same screening to this population. This would include a serum alpha fetoprotein (AFP) and liver imaging, typically ultrasound; however, computed tomography and magnetic resonance imaging may also be used. Interval surveillance for HCC in patients with documented cirrhosis should take place every 6-12 months based on prior establishment of HCC median doubling time. It is unclear whether or not follow-up AFP and imaging surveillance should be done in the Fontan with isolated fibrosis. & In the general population, a liver biopsy is indicated in those found to have parenchymal liver disease (such as fibrosis, cirrhosis, or mass) in order to determine the etiology and prognosis of liver disease [45] . In the Fontan population, it is not unreasonable to apply the same general criteria. This type of application would result in the majority of Fontan patients receiving a biopsy to confirm diagnosis and estimate prognosis of the liver disease. Biopsy results would play an important role in determining HCC follow-up if cirrhosis is indeed present.
Pharmacologic treatment
& There are no current medical therapies that are recommended for the treatment of fibrosis in the Fontan population. The reninangiotensin system (RAS) is recognized as an important regulator of liver fibrosis, and there is evidence supporting anti-inflammatory and anti-fibrogenic effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in liver disease [46] . However, no similar studies have been performed in the Fontan population. Moreover, the complex hemodynamics in Fontan patients can be difficult to evaluate, and afterload-reducing agents such as these can have differential effects relative to central venous pressure and underlying ventricular function. Caution in the Fontan patient with liver disease must be taken, as use of this group of medications can precipitate hepato-renal syndrome. Therefore, these pharmacologic agents are not routinely recommended for this group of patients.
Assist devices
& Reports of ventricular assist device use in Fontan patients are rare and in general document technical aspects of the implant, clinical improvement, and a successful bridge to transplantation [47] [48] [49] [50] . There is only one reported case using a total artificial heart in a singleventricle Fontan patient who recovered and eventually went on to have heart transplant [51] . Given the paucity of data using ventricular assist devices in this group, a registry was established in 2013 to collect further data and experience [52] . Mechanical circulatory support was not designed for complex congenital cardiac conditions. However, there has been an increase in research efforts directed at understanding and developing a device that can safely be used in patients with a Fontan procedure [53] [54] [55] [56] [57] [58] . There are potential advantages to restoring pulsatile flow to the lungs in this population. A pulmonary pump capable of restoring pulsatile flow, even in the face of elevated pulmonary vascular resistance, may provide a durable bridge to recovery or transplant for Fontan patients by reducing central venous pressures and congestion. To our knowledge, there has been no evaluation of transient effects on the liver in this group of patients, information which could be useful in determining the "recoverability" of liver function and assist in determination of candidacy for orthotopic heart transplant (OHT) versus combined heart liver transplant (CHLT). 
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• Single center case series • Heart failure: NICM (18) ICM, CHD (6), ICM (2)
• Liver failure: cardiac cirrhosis (23) Table 2) . Combined organ transplant outcomes are similar to those in singleorgan transplant, irrespective of underlying etiology for CHLT [79] [80] [81] . However, as reviewed in this manuscript, determining the degree of liver disease in adult Fontan patients is difficult. We know that histologic presence of fibrosis is present in nearly all Fontan patients, and many have cirrhosis. Despite this, there is evidence that Fontan patients with cirrhosis have similar 1-year postoperative OHT mortality and liver function tests as compared to those with lesser degrees of liver involvement [82•] . The crux of the problem is defining when liver disease in the Fontan patient is irreversible and clinically significant. This problem exists not only in Fontan patients but also in other groups with cardiac cirrhosis, such as amyloid patients. Recently, in a noncongenital heart disease cohort, a liver risk score inclusive of biopsy results and the MELD-XI was found to be correlative with morbidity and mortality [83••] . Future research using this type of predictive tool, along with prospective validation, is required and holds prospect for a more inclusive model to evaluate this complex population when the question of transplant arises.
Conclusion
Adult patients with a prior Fontan procedure are a unique population requiring specialized care for the systemic nature of their disease. Clinicians need to focus on extra-cardiac manifestations of the late Fontan patient, including recognition and management of liver disease as reviewed here. There is no consensus regarding care
